Please use this identifier to cite or link to this item: http://hdl.handle.net/2381/37406
Title: Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth In Vitro and Proliferation In Vivo
Authors: Nale, Janet Y.
Spencer, Janice
Hargreaves, Katherine R.
Buckley, Anthony M.
Trzepinski, Przemysław
Douce, Gillian R.
Clokie, Martha R. J.
First Published: 1-Feb-2016
Publisher: American Society for Microbiology
Citation: Antimicrobial Agents and Chemotherapy, 2016, 60 (2), pp. 968-981
Abstract: The microbiome dysbiosis caused by antibiotic treatment has been associated with both susceptibility to and relapse of Clostridium difficile infection (CDI). Bacteriophage (phage) therapy offers target specificity and dose amplification in situ, but few studies have focused on its use in CDI treatment. This mainly reflects the lack of strictly virulent phages that target this pathogen. While it is widely accepted that temperate phages are unsuitable for therapeutic purposes due to their transduction potential, analysis of seven C. difficile phages confirmed that this impact could be curtailed by the application of multiple phage types. Here, host range analysis of six myoviruses and one siphovirus was conducted on 80 strains representing 21 major epidemic and clinically severe ribotypes. The phages had complementary coverage, lysing 18 and 62 of the ribotypes and strains tested, respectively. Single-phage treatments of ribotype 076, 014/020, and 027 strains showed an initial reduction in the bacterial load followed by the emergence of phage-resistant colonies. However, these colonies remained susceptible to infection with an unrelated phage. In contrast, specific phage combinations caused the complete lysis of C. difficile in vitro and prevented the appearance of resistant/lysogenic clones. Using a hamster model, the oral delivery of optimized phage combinations resulted in reduced C. difficile colonization at 36 h postinfection. Interestingly, free phages were recovered from the bowel at this time. In a challenge model of the disease, phage treatment delayed the onset of symptoms by 33 h compared to the time of onset of symptoms in untreated animals. These data demonstrate the therapeutic potential of phage combinations to treat CDI.
DOI Link: 10.1128/AAC.01774-15
ISSN: 0066-4804
eISSN: 1098-6596
Links: http://aac.asm.org/content/60/2/968
http://hdl.handle.net/2381/37406
Version: Publisher Version
Status: Peer-reviewed
Type: Journal Article
Rights: Copyright © Nale et al, 2016. This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Appears in Collections:Published Articles, Dept. of Infection, Immunity and Inflammation

Files in This Item:
File Description SizeFormat 
Antimicrob. Agents Chemother.-2016-Nale-968-81.pdfPublished (publisher PDF)2.06 MBAdobe PDFView/Open


Items in LRA are protected by copyright, with all rights reserved, unless otherwise indicated.